In 1997, Lilly and Emisphere entered into a multiyear research and option agreement.
Osteoporosis can lead to enhanced bone fragility and an increase in the risk of fracture.
Unlike antiresorptive agents that work to reduce bone loss, clinical trials with Forteo suggest that the agent appears to rapidly stimulate new bone formation. Humatrope is another Lilly product currently indicated for certain growth disorders. The two companies will collaborate to bring oral forms of Forteo and Humatrope into clinical testing. The new agreement also provides for supplemental research and development funding. An oral formulation of Forteo has the potential to accelerate the growth of this product in the marketplace and build upon our success in delivering innovative products to treat osteoporosis.